PUBLISHER: DelveInsight | PRODUCT CODE: 1226592
PUBLISHER: DelveInsight | PRODUCT CODE: 1226592
"Iptacopan Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Iptacopan for Atypical Hemolytic Uremic Syndrome in the 7MM. A detailed picture of the Iptacopan for Atypical Hemolytic Uremic Syndrome in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Iptacopan for Atypical Hemolytic Uremic Syndrome. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Iptacopan market forecast, analysis for Atypical Hemolytic Uremic Syndrome in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Atypical Hemolytic Uremic Syndrome.
Iptacopan, also known as LNP023, is a first-in-class, orally administered, small-molecule, potent, and highly selective factor B (FB) inhibitor, a key serine protease of the alternative pathway of the complement cascade. The AP acts as an amplification loop of complement activation and contributes to various human diseases. Inhibition of factor B is being exploited as a mechanism to treat complement-mediated conditions such as C3 glomerulopathy (glomerulonephritis, including IgA nephropathy), paroxysmal nocturnal hemoglobinuria, and aHUS.
Upon administration, Iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders. In addition to aHUS, Iptacopan is currently in clinical development for paroxysmal nocturnal hemoglobinuria (PNH), as well as C3 glomerulopathy (C3G) and several other renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy (IgAN) and membranous nephropathy (MN).
Currently, Iptacopan is in the Phase III development stage. Recently, a Phase III clinical trial was started in August 2021, investigating the drug in aHUS. The ongoing Phase III clinical trial is a multicenter, single-arm, open-label trial to evaluate the efficacy and safety of twice daily oral LNP023 in adult aHUS patients who are naive to complement inhibitor therapy and is expected to be completed by December 2024.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of Iptacopan in Atypical Hemolytic Uremic Syndrome in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of Iptacopan for Atypical Hemolytic Uremic Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.